Press releases

Glycorex Transplantation AB (GTAB): Interim Report April-June 2021

Wed, Aug 25 2021, 6:00 GMT+0200 | Interim report | Regulatory release

April – June 2021 (compared to the corresponding period last year)

  • Net sales: SEK 8,0 million (3,3).
  • Operating income: SEK -2,2 million (-6,4).
  • Net income for the period: SEK -2,3 million (-6,8).
  • Earnings per share: SEK -0,03 (-0,09), no dilution effects.
  • COVID-19 reorientation support SEK 0,85 million received.
  • Positive trend and good sales growth in the majority of the company's markets, including record sales to Spain and 74 percent growth in the company's largest market Germany.
  • Publication in The Journal of Heart and Lung Transplantation shows significant benefits from using Glycosorb® ABO intraoperatively for blood group-incompatible heart transplants in children.
  • Good results with the company's UBP product presented at the Spanish Blood and Transfusion Congress for 2021, SETS.
  • Strong end to the quarter and positive signals from the market inspire optimism.
  Second quarter 6 months Full year
SEK Thousands Apr-Jun 2021 Apr-Jun 2020 Jan-Jun 2021 Jan-Jun 2020 Jan-Dec 2020
Net sales 7, 954 3, 267 12, 877 10, 941 27, 000
Change in stocks of finished goods -222 -786 -381 -1, 038 -81
Own work capitalized 225 216 416 818 1, 640
Other operating income 928 316 1, 031 445 1, 654
Total 8, 885 3, 013 13, 943 11, 166 30, 213
Operating expenses
Raw materials and supplies -772 -803 -1, 199 -1, 769 -3, 929
Other external expenses -2, 564 -2, 111 -4, 931 -4, 076 -9, 284
Personnel expenses -5, 582 -4, 335 -10, 955 -8, 122 -16, 419
Depreciation and amortization of fixed assets -2, 116 -1, 983 -4, 230 -3, 241 -7, 830
Other operating expenses -60 -219 -124 -219 -475
Operating income -2, 209 -6, 438 -7, 496 -6, 261 -7, 724
Net financial items -124 -321 -209 -165 -326
Income before tax -2, 333 -6, 759 -7, 705 -6, 426 -8, 050
Taxes 29 - 55 - 10
Net income -2, 304 -6, 759 -7, 650 -6, 426 -8, 040
Earnings per share, SEK -0.03 -0.09 -0.1 -0.09 -0.11
 

THE COMPLETE INTERIM REPORT FOR THE SECOND QUARTER IS ATTACHED (IN SWEDISH)

This is a translation and an excerpt of the first page of the Swedish version of the Interim report. When in doubt, the Swedish wording prevails.

This disclosure contains information that Glycorex Transplantation is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person, on August 25, 2021 08:00 CET.

Contact

Johan Nilsson, Interim CEO, Glycorex Transplantation AB.

E-mail: info@glycorex.se, phone: 046-286 52 30

Brief information about the company

Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.

The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.


 

News in swedish

Glycorex Transplantation AB (GTAB): Interim Report April-June 2021

Wed, Aug 25 2021, 6:00 GMT+0200 | Interim report | Regulatory release

April – June 2021 (compared to the corresponding period last year)

  • Net sales: SEK 8,0 million (3,3).
  • Operating income: SEK -2,2 million (-6,4).
  • Net income for the period: SEK -2,3 million (-6,8).
  • Earnings per share: SEK -0,03 (-0,09), no dilution effects.
  • COVID-19 reorientation support SEK 0,85 million received.
  • Positive trend and good sales growth in the majority of the company's markets, including record sales to Spain and 74 percent growth in the company's largest market Germany.
  • Publication in The Journal of Heart and Lung Transplantation shows significant benefits from using Glycosorb® ABO intraoperatively for blood group-incompatible heart transplants in children.
  • Good results with the company's UBP product presented at the Spanish Blood and Transfusion Congress for 2021, SETS.
  • Strong end to the quarter and positive signals from the market inspire optimism.
  Second quarter 6 months Full year
SEK Thousands Apr-Jun 2021 Apr-Jun 2020 Jan-Jun 2021 Jan-Jun 2020 Jan-Dec 2020
Net sales 7, 954 3, 267 12, 877 10, 941 27, 000
Change in stocks of finished goods -222 -786 -381 -1, 038 -81
Own work capitalized 225 216 416 818 1, 640
Other operating income 928 316 1, 031 445 1, 654
Total 8, 885 3, 013 13, 943 11, 166 30, 213
Operating expenses
Raw materials and supplies -772 -803 -1, 199 -1, 769 -3, 929
Other external expenses -2, 564 -2, 111 -4, 931 -4, 076 -9, 284
Personnel expenses -5, 582 -4, 335 -10, 955 -8, 122 -16, 419
Depreciation and amortization of fixed assets -2, 116 -1, 983 -4, 230 -3, 241 -7, 830
Other operating expenses -60 -219 -124 -219 -475
Operating income -2, 209 -6, 438 -7, 496 -6, 261 -7, 724
Net financial items -124 -321 -209 -165 -326
Income before tax -2, 333 -6, 759 -7, 705 -6, 426 -8, 050
Taxes 29 - 55 - 10
Net income -2, 304 -6, 759 -7, 650 -6, 426 -8, 040
Earnings per share, SEK -0.03 -0.09 -0.1 -0.09 -0.11
 

THE COMPLETE INTERIM REPORT FOR THE SECOND QUARTER IS ATTACHED (IN SWEDISH)

This is a translation and an excerpt of the first page of the Swedish version of the Interim report. When in doubt, the Swedish wording prevails.

This disclosure contains information that Glycorex Transplantation is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person, on August 25, 2021 08:00 CET.

Contact

Johan Nilsson, Interim CEO, Glycorex Transplantation AB.

E-mail: info@glycorex.se, phone: 046-286 52 30

Brief information about the company

Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.

The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.


 

Subscribe to our releases

Choose categories

Contact information

The subscription service is provided by Cision.se and your information will be stored on their servers. The information will only be used to send you notifications when new releases are published. No personal information will be shared with any outside parties. Read more about our Privacy Policy.

News

Pontus Nobréus, CEO presenting Glycorex Transplantation on Redeye Growth Day june 2.
Presentationen >>

Download the presentationen >>

 

 

Pontus Nobréus, CEO presenting Glycorex Transplantation  BioStock Life Science Spring Summit on May 26
https://youtu.be/5fpTsNENiO8

Download the presentation >>

Glycorex Transplantation is a proud collaborator with The Hospital Clínic de Barcelona in Spain. It recently became the first hospital in Spain to carry out more than 1,000 living donor kidney transplants. To celebrate this milestone, a campaign called “A thousand transplants, a thousand stories” was launched to increase public awareness and encourage living donor kidney donations. https://www.clinicbarcelona.org/en/news/the-hospital-clinic-the-first-hospital-in-spain-to-carry-out-1-000-living-donor-kidney-transplants

REDEYE GROWTH DAY
Pontus Nobréus, CEO of Glycorex Transplantation will present at the Redeye Growth Day on June 2, 2021 at 08:50 CET.
Link to live streaming: https://www.redeye.se/events/808637/redeye-growth-day-2021

Glycorex Transplantation participates in the BioStock Life Science Spring Summit 2021. CEO Pontus Nobréus will present the company at the BioStock Life Science Spring Summit on May 26-27. For more information please visit: www.summit.biostock.se

Tomorrow, april 29th, Dr Guirado from Spain will discuss ABO incompatible kidney transplantations in a live Zoom seminar, arranged by our distributor in Mexcio, Ryse Médica and Sociedad Mexicana De Transplantes.

https://us02web.zoom.us/j/85789158554

Scheelevägen 27 | SE-223 63 Lund, Sweden

Phone: +46 46 286 52 30  | Fax: +46 46-286 52 39
E-mail: info@glycorex.com

Org.nr: 556519-7372

© 2021 Glycorex Transplantation AB. Registered office in Lund, Sweden . All rights reserved.